Northpointe Capital’s Abiomed Inc ABMD Stock Holding History

Northpointe Capital’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,877	Closed	-$4.89M	–	197
2018 Q3	$4.89M	Buy	+10,877	New	+$4.29M	0.71%	46

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Northpointe Capital's ABMD Position: Q4 2018 in Review

Northpointe Capital sold out of Abiomed Inc (ABMD) in Q4 2018, closing a stake of 10,877 shares — an estimated $4.89M sold.

Northpointe Capital first reported a position in ABMD in Q3 2018 and held it in 1 quarter. The position peaked at $4.89M in Q3 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q4 2018.

Northpointe Capital reported no remaining Abiomed Inc position as of Q4 2018 after selling out during the quarter.
Northpointe Capital sold 10,877 Abiomed Inc shares in Q4 2018, an estimated $4.89M.
Northpointe Capital first reported a position in Abiomed Inc in Q3 2018 and held it in 1 quarter.
Northpointe Capital's Abiomed Inc position peaked at $4.89M in Q3 2018.
529 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2018.

Based on Northpointe Capital's 13F filing for Q4 2018, filed 24 Jan 2019.